SPA
STOK icon

Sherbrooke Park Advisers’s Stoke Therapeutics STOK Stock Holding History

Sherbrooke Park Advisers’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12,295
Closed -$48.4K – 667
2023
Q3 		$48.4K Buy
+12,295
New +$80.8K 0.02% 489

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sherbrooke Park Advisers's STOK Position: Q4 2023 in Review

Sherbrooke Park Advisers sold out of Stoke Therapeutics (STOK) in Q4 2023, closing a stake of 12,295 shares — an estimated $48.4K sold.

Sherbrooke Park Advisers first reported a position in STOK in Q3 2023 and held it in 1 quarter. The position peaked at $48.4K in Q3 2023. 81 funds tracked by Wall St. Rank hold STOK as of Q4 2023.

  • Sherbrooke Park Advisers reported no remaining Stoke Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 12,295 Stoke Therapeutics shares in Q4 2023, an estimated $48.4K.
  • Sherbrooke Park Advisers first reported a position in Stoke Therapeutics in Q3 2023 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Stoke Therapeutics position peaked at $48.4K in Q3 2023.
  • 81 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2023.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2023, filed 14 Feb 2024.